Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2016

View Archived Issues

Susceptible mouse model of ZIKV infection as a tool for testing novel vaccines and antivirals

Validation of C1M as a prognostic biomarker in rheumatoid arthritis structural progression

Incyte initiates phase I/II study of INCAGN-01876 for advanced or metastatic solid tumors

Cytonics' recombinant A2M variants attenuate cartilage degeneration in osteoarthritis models

FDA grants orphan drug designation to ANAVEX 2-73

Cellular Dynamics and National Eye Institute sign CRADA

Spring Bank Pharmaceuticals begins dosing in ACHIEVE phase II program

STAT3 inhibition shows positive preclinical results for the treatment of breast cancer

Asahi Kasei Pharma and Orion establish strategic collaboration in pain

NIH committee recommends approval of Dimension Therapeutics' phase I/II study of DTX-301

Epizyme closes deal with Genentech for tazemetostat + atezolizumab study

Yumanity announces collaboration with the New York Stem Cell Foundation Research Institute

Nymox Pharmaceutical announces long-term fexapotide prostate cancer study results

NCI Cancer Centers and Celgene enter landmark research consortium and collaborations

Celgene's CC-115 shows signs of activity in phase I cancer trial

ArQule initiates phase I study of ARQ-751 in patients with advanced solid tumors

Bionomics receives funds as part of licensing agreement for PRMT5 inhibitors

FDA grants orphan drug designation to napabucasin for the treatment of gastric cancer

Janssen R&D reports antiviral compounds

Merck & Co. discloses HIV integrase inhibitors

Bayer Schering Pharma patents HSKM-B inhibitors

Aquinnah Pharmaceuticals patent describes TDP-43 inhibitors

Rapid responses seen with TNT-009 in patients with cold agglutinin disease

ASLAN Pharmaceuticals' varlitinib receives FDA orphan drug designation

Kailos Genetics and HCI collaborate to develop ctDNA test to monitor breast cancer recurrence

Allogeneic stem cell treatment with SB-623 shows promise in stroke patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...